VC Catalog · venture ecosystem research library
VC Catalog home Beta

Company

StingrayTx

Rocket Ship RatingBased on the data VC Catalog holds.

Rocket Ship Rating: 75 out of 100

Stingray Therapeutics - Best - in - Class ENPP1 Inhibitor for Cancer Immunotherapy

  • Biotech & therapeutics
Business model
B2B
Open relationship map
Claim, correct or request removal

Record updated 28 September 2026

About

Stingray Therapeutics is developing Vizenpistat (SR-8541A), the world's most advanced ENPP1 inhibitor — in active clinical trials with a strong safety profile and broad applicability across multiple cancer indications.

Loading relationship preview

Cookies on VC Catalog

We use necessary cookies to run the site (sign-in, security, remembering this choice). With your permission we also use Google Analytics to understand how the site is used. Analytics cookies are set only if you accept all cookies. Privacy policy